CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Alliance Forum Foundation |
George Hara |
Conference II |
2016 World Alliance Forum in San Francisco (WAFSF) “US-Japan Innovative Healthcare Technologies Conference” |
$20,000 |
| University of California, Irvine |
Dr. LESLIE M Thompson |
Conference II |
HD-CARE INAUGURAL SYMPOSIUM |
$1,500 |
| Keystone Symposia on Molecular and Cellular Biology |
Thale Jarvis |
Conference II |
Neurogenesis during Development and in the Adult Brain (joint with Transcriptional and Epigenetic Control in Stem Cells) |
$35,000 |
| American Association of Blood Banks |
Dr. Naynesh R. Kamani |
Conference II |
14th International Cord Blood Symposium: Give Life Twice |
$15,000 |
| University of California, San Diego |
Prof. John M. Ravits |
Conference II |
California ALS Research Summit 2016 |
$11,400 |
| Stanford University |
Dr. Joseph C. Wu |
Conference II |
Drug Discovery & Stem Cell Models for Cardiovascular Disease Conference |
$7,500 |
| Gordon Research Conferences |
Dr. Ophir Klein MD, PhD |
Conference II |
2016 Gordon Research Conference on Craniofacial Morphogenesis and Tissue Regeneration |
$5,000 |
| City of Hope, Beckman Research Institute |
Fouad Kandeel |
Conference II |
2016 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$10,000 |
| International Society for Experimental Hematology |
Dr. David Traver |
Conference II |
International Society for Experimental Hematology, 45th Annual Scientific Meeting |
$25,000 |
| University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Conference II |
Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop |
$29,807 |
| Alliance Forum Foundation |
George Hara |
Conference II |
2015 World Alliance Forum in San Francisco (2015 WAFSF) “Regenerative Medicine: Let’s Talk Business!” |
$10,000 |
| Sanford Consortium for Regenerative Medicine |
Dr. Edward Holmes |
Conference II |
Stem Cell Meeting on the Mesa |
$50,000 |
| University of California, Irvine |
Dr. Sidney Golub |
Conference II |
Human Research In Times of Controversy: From Stem Cells To Fetal Tissue |
$13,562 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Clinical Trial Stage Projects |
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy |
$13,999,983 |
| University of California, San Francisco |
Mort Cowan |
Clinical Trial Stage Projects |
Gene Therapy for Artemis-Deficient Severe Combined Immunodeficiency Using a Self-Inactivating Lentiviral Vector |
$14,999,999 |
| Tenaya Therapeutics, Inc. |
Dr. Matthew Pollman |
Clinical Trial Stage Projects |
Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) |
$8,000,000 |
| Tr1X Inc. |
Dr. Maria Grazia Roncarolo |
Clinical Trial Stage Projects |
TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies |
$8,000,000 |
| University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS-ADA lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$14,325,181 |
| Senti Biosciences, Inc. |
Rochelle Emery |
Clinical Trial Stage Projects |
Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies |
$8,000,000 |
| Fate Therapeutics, Inc. |
Bob Valamehr |
Clinical Trial Stage Projects |
A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus |
$7,934,448 |
| ImmPACT-Bio, Inc. |
DR Jonathan Benjamin |
Clinical Trial Stage Projects |
A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus |
$841,214 |
| Nexcella, Inc. |
Ilya Rachman MD PhD |
Clinical Trial Stage Projects |
Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis |
$7,999,467 |
| University of California, San Francisco |
Dr. Hideho Okada |
Clinical Trial Stage Projects |
Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma |
$10,927,618 |
| Aspen Neuroscience |
Dr. Edward Wirth III |
Clinical Trial Stage Projects |
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease |
$8,000,000 |
| Alto Neuroscience |
Amit Etkin |
Clinical Trial Stage Projects |
A Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach |
$0 |
| Allogene Therapeutics |
Dr. John Le Gall |
Clinical Trial Stage Projects |
A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC) |
$9,238,404 |
| University of California, San Francisco |
Noriyuki Kasahara |
Clinical Trial Stage Projects |
A Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma |
$11,807,220 |
| Luxa Biotechnology |
Dr. Jeffrey H Stern |
Clinical Trial Stage Projects |
RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration |
$4,009,675 |
| Rocket Pharmaceuticals, Inc. |
Dr. Jonathan Schwartz |
Clinical Trial Stage Projects |
A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV9 Vector Containing RP-A501 in Male Patients with Danon Disease |
$5,808,735 |
| University of California, Davis |
Dr. Diana L. Farmer |
Clinical Trial Stage Projects |
The CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele |
$8,996,477 |
| Stanford University |
Dr. Reena Parada Thomas |
Clinical Trial Stage Projects |
Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme |
$11,999,991 |
| City of Hope, Beckman Research Institute |
Elizabeth Budde |
Clinical Trial Stage Projects |
Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
$11,983,547 |
| University of California, San Diego |
Prof. Olivia Kim-McManus |
Clinical Trial Stage Projects |
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A |
$960,713 |
| Stanford University |
Anusha Kalbasi |
Clinical Trial Stage Projects |
Stem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors |
$10,211,085 |
| University of California, Los Angeles |
Dr. Jeffrey L Veale |
Clinical Trial Stage Projects |
The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program |
$6,717,608 |
| Regenerative Patch Technologies LLC |
Dr Jane S Lebkowski |
Clinical Trial Stage Projects |
A Phase 2b, Randomized, Assessor-Masked Clinical Trial to Assess the Safety and Efficacy of the CPCB-RPE1 Implant in Subjects with Geographic Atrophy |
$12,373,748 |
| City of Hope, Beckman Research Institute |
Dr. Angelo Manuel Almeida Cardoso Ph.D., MD |
Clinical Trial Stage Projects |
Evaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV |
$11,299,976 |
| Combangio, Inc. |
R. Kim Brazzell |
Clinical Trial Stage Projects |
Phase 2b Clinical Study of KPI-012 Topical Ophthalmic Human Mesenchymal Stem Cell Secretome for the Treatment of Persistent Corneal Epithelial Defect |
$15,000,000 |
| Immusoft Corporation |
Dr Robert Hayes |
Clinical Trial Stage Projects |
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 |
$8,000,000 |
| Eureka Therapeutics, Inc. |
Pei Wang |
Clinical Trial Stage Projects |
Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer |
$10,600,072 |
| Stanford University |
Dr. Matthew H Porteus |
Clinical Trial Stage Projects |
Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients |
$10,642,420 |
| Angiocrine Bioscience, Inc. |
Dr. Paul Finnegan |
Clinical Trial Stage Projects |
AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205 |
$10,930,014 |
| Genascence Corporation |
Dr. Thomas W Chalberg Jr. |
Clinical Trial Stage Projects |
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA |
$11,637,194 |
| City of Hope, Beckman Research Institute |
Ryotaro Nakamura |
Clinical Trial Stage Projects |
Treatment of Severe Aplastic Anemia by induction of mixed chimerism using CD4+ T cell depleted haploidentical donor stem cell transplant |
$9,054,216 |
| Tachyon Therapeutics, Inc |
Ivan King |
Clinical Trial Stage Projects |
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers |
$3,525,000 |
| Stanford University |
Alice Bertaina |
Clinical Trial Stage Projects |
Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant |
$11,998,188 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Clinical Trial Stage Projects |
Phase 1/2 Study of NRTX-1001 Neural Cell Therapy in Subjects with Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
$7,999,999 |
| Excision BioTherapeutics |
Mr. Daniel Dornbusch |
Clinical Trial Stage Projects |
Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy |
$4,940,000 |
| Wake Forest University Health Sciences |
James Yoo |
Clinical Trial Stage Projects |
Phase I Treatment of Urethral Strictures in Humans |
$1,250,000 |
| Stanford University |
Dr. Rosa Bacchetta |
Clinical Trial Stage Projects |
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome |
$11,999,179 |
